Where Things Stand: House Panel Confirms What We Suspected In Real Time

This is your TPM evening briefing.
WASHINGTON, DC - DECEMBER 08: US President Donald Trump speaks at the Operation Warp Speed Vaccine Summit on December 08, 2020 in Washington, DC. The president signed an executive order stating the US would provide ... WASHINGTON, DC - DECEMBER 08: US President Donald Trump speaks at the Operation Warp Speed Vaccine Summit on December 08, 2020 in Washington, DC. The president signed an executive order stating the US would provide vaccines to Americans before aiding other nations. (Photo by Tasos Katopodis/Getty Images) MORE LESS

We covered quite a bit of the horse-pill propaganda being peddled as a COVID cure by many in anti-vax circles and by some members of the Trump White House at the time when hydroxychloroquine first emerged as a word that people knew how to pronounce. It provided some dark comedic relief as an absurd storyline to chase during an otherwise very bleak and scary time. (Hydroxychloroquine, you’ll recall, would eventually be replaced in the vaccine-skeptic imagination by an actual livestock pill, ivermectin.)

Some examples:

Biden Slams Trump For Taking Unproven COVID-19 Drug: ‘What In God’s Name Is He Doing?’

Betrayed Trump Throws A Fit After Fox Host Criticizes POTUS’ Unproven COVID-19 Cure

Trying To Email Chloroquine Advocate, Corsi Accidentally Tips Off Ex-Mueller Prosecutor

Hydroxychloroquine, We Hardly Knew Ye

WH Adviser Cites ‘Dilbert’ Cartoonist While Boosting Hydroxychloroquine

Don’t Eat Horse Meds To Treat COVID-19

You get the picture.

The anti-malaria drug was flying off the shelves for months as Trump and some of those in his inner circle pushed the treatment as a cure for COVID-19. It never was. While it temporarily allowed the use of the drug as a form of symptom nursing, by April 2020 the FDA issued a warning against Trump’s favorite unproven cure, saying the meds were dangerous to use against COVID symptoms because they could cause life-threatening heart complications. Trump claimed he took it anyway to recover from his COVID-19 diagnosis.

It was just one layer of the Trump administration’s broader botched handling of the coronavirus pandemic. Trump and many of his allies hyped hydroxychloroquine as a cure primarily to downplay the severity of COVID — an effort birthed out of concerns over the damage a shut-down nation would inflict on the U.S. economy. But the COVID-19 public health mitigation measures were, of course, a matter of life and death.

We could read the writing on the wall back in 2020, but a new House panel report out today reveals what we saw unfold in real time — Trump White House staffers attempted to pressure the FDA and other U.S. health experts into reauthorizing hydroxychloroquine as a COVID-19 treatment. The findings were all part of the House Select Subcommittee on the Coronavirus Crisis’s broader report on the Trump administration’s efforts to bypass the FDA for political purposes throughout much of the pandemic.

The report gets into the role that some of Trump’s favorite cable news commentators — like Fox News’ Laura Ingraham and Dr. Oz — had in pushing the White House to embrace the treatment in the first place. It also sheds light on the role Trump aide Peter Navarro and controversial doctor Steven Hatfill played in pressuring the “FDA and federal officials who they contended were wrongly impeding widespread access to hydroxychloroquine,” the report said.

Congressional investigators also found evidence that the Trump White House attempted to speed up the FDA’s health and safety studies in order to pressure the agency into authorizing the COVID-19 vaccine before the 2020 election.

You can read the report in full here.

The Best Of TPM Today

Here’s what you should read this evening:

Judge Blocks Biden Admin Guidance Requiring Physicians To Perform Abortions Amid Medical Emergencies

Biden Set To Cancel $10K For Student Loan Borrowers Earning Less Than $125,000

Scott Perry Sues To Block DOJ From Accessing Contents Of His Cell Phone

Timeline: What We Know About The Missing Text Message Scandal

New in TPM Cafe: Inflation Reduction Act Won’t Get Around SCOTUS Climate Ruling. But It Strengthens EPA’s Future Abilities

From ProPublica: Why Outlawing Ghost Guns Didn’t Stop America’s Largest Maker Of Ghost Gun Parts

Stefanik-Backed Racist GOPer Carl Paladino Goes Down To Defeat

Yesterday’s Most Read Story

Report: Jan. 6 Panel Aides Traveled To Copenhagen To View Footage Of Roger Stone — Summer Concepcion

What We Are Reading

A GOP misinformation campaign targets Democrats’ climate spending packages — Laura Benshoff

Castle Rock man charged in federal “We Build The Wall” case wants retrial in Colorado — Larry Neumeister

Tucker Carlson: Despite Biden’s unpopularity, Democrats still have a chance of holding Congress in November — Tucker Carlson

Dear Reader,

When we asked recently what makes TPM different from other outlets, readers cited factors like honesty, curiosity, transparency, and our vibrant community. They also pointed to our ability to report on important stories and trends long before they are picked up by mainstream outlets; our ability to contextualize information within the arc of history; and our focus on the real-world consequences of the news.

Our unique approach to reporting and presenting the news, however, wouldn’t be possible without our readers’ support. That’s not just marketing speak, it’s true: our work would literally not be possible without readers deciding to become members. Not only does member support account for more than 80% of TPM’s revenue, our members have helped us build an engaged and informed community. Many of our best stories were born from reader tips and valuable member feedback.

We do what other news outlets can’t or won’t do because our members’ support gives us real independence.

If you enjoy reading TPM and value what we do, become a member today.

Latest Edblog
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Investigations Desk:
Reporters:
Newswriter:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: